Engineered RBC-derived nanovesicles functionalized with tumor-targeting ligands: A comparative study on breast cancer targeting efficiency and biocompatibility
This work presents systematic comparative evaluation of ligand-engineered RNVs, underscoring cRGD as the most potent targeting moiety for breast cancer. These findings illuminate critical design principles for the rational development of tumor-directed RNV-based drug delivery systems and strengthen the translational promise of biomimetic nanocarriers for clinical oncology.
Authors
- Xingwei Huang (ORCID: https://orcid.org/0000-0002-4814-9037)
- Huozhong Yuan (ORCID: https://orcid.org/0000-0001-6717-5671)
- Weilun Pan (ORCID: https://orcid.org/0000-0002-2119-5033)
- Bo Li (ORCID: https://orcid.org/0000-0002-6129-321X)
- Jin Jiang (ORCID: https://orcid.org/0000-0003-2815-6245)
- Jingyun Guo (ORCID: https://orcid.org/0000-0002-7827-9123)
- Xin Wang (ORCID: https://orcid.org/0009-0003-5222-8816)
- Yuan Zhang (ORCID: https://orcid.org/0000-0002-2754-1291)
- Fulan Yang (ORCID: https://orcid.org/0000-0001-5714-4724)
- Yue Qiao
Institutions
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Ganzhou People's Hospital (CN)
- Guangzhou Blood Center (CN)
- Nanfang Hospital (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- Open Medicine
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1515/med-2025-1306
- Primary Topic
- Nanoplatforms for cancer theranostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Southern Medical University
- Nanfang Hospital